Prebiopsy MRI can ‘transform’ prostate cancer care, study finds

  Prebiopsy multiparametric MRI (mpMRI) paired with targeted biopsy can improve the detection of clinically significant prostate cancer, according to a study published in JAMA Network Open. Identifying high-risk from low-risk prostate cancers can spare men from unnecessary invasive treatments and treatment-associated morbidity, wrote first author Martha M. C. Elwenspoek, PhD, but doing so remains difficult. “There is, therefore, an...Read More

PSMA PET finds more cancer than Axumin

  A PSMA PET scan (Ga-68-PSMA-11) detected more sites of cancer than an Axumin PET scan in the same recurrent patients. This prospective clinical trial was  conducted among 50 men at UCLA in 2018. All men had post-prostatectomy PSA from 0.2- 2.0 ng/ml.  The Calais et al. findings are summarized in the following table: Ga-68-PSMA-11 Axumin Detected - % of patients 56%...Read More

Newer PSA Test Reportedly Would Prevent 40 Percent of Biopsies

  A new blood test aims for better detection of prostate cancer, but some say it’s not the breakthrough we’ve been hoping for. Researchers continue to try to improve upon the blood test used to screen for prostate cancer— the prostate-specific antigen (PSA) test. A new test claims to help physicians get more accuracy and avoid unnecessary biopsies. The PSA test...Read More

Axumin PET Scans: A Breakthrough for Prostate Cancer

  Axumin is an FDA-approved, Medicare-covered scan that can achieve early detection of recurrent prostate cancer after surgery or radiation. For years we have been able to detect prostate cancer recurrences with PSA, but standard body and bone scans have been unable to determine the location of the cancer until the PSA level is excessively elevated (10 to 30 or higher). Axumin can detect recurrent...Read More